研究目的
To investigate the effectiveness and safety of SoracteLite?—transperineal percutaneous laser ablation (TPLA) in the treatment of patients with symptomatic benign prostatic hyperplasia (BPH) at 6 and 12 months follow-up.
研究成果
SoracteLiteTM TPLA seems to be a safe and effective technique in the treatment of patients with BPH, demonstrating significant results sustained up to 12 months. SoracteLiteTM TPLA is well tolerated by patients, does not require general anesthesia, has a low morbidity and requires short hospitalization; therefore, SoracteLiteTM TPLA is rightfully taking part of the array of new techniques susceptible to wide application in patients with a long life expectancy.
研究不足
This is a retrospective analysis, and no comparison with patients treated with other techniques has been performed. Prospective studies are necessary for further validate the technique, possibly comparing SoracteLiteTM TPLA with other techniques such as TURP. Also, patients were treated in separate centers with a novel technique, thus results can be affected by the initial experience of the operators. Furthermore, only a selected subgroup of patients with at least 6 months of follow-up data available has been included in the present analysis. Studies with longer follow-up are necessary to better understand if results are sustained in the midterm and long-term period. Furthermore, ejaculatory function was not evaluated with a specific questionnaire, and thus the rate of ejucalotary complications in our series might be underestimated.
